DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Dato-DXd
Drug: Durvalumab

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-22

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 50

Registration Number: NCT06508216

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue

Not Applicable

Not yet recruiting

Conditions: Moderate or Severe Score of Cancer-related Fatigue (CRF)
Cancer Diagnosis

Interventions: Device: Educational material plus self-management program - guided version with mental health professional
Device: Educational material plus self-management program - self-administered version
Device: Educational content

First Posted Date: 2024-07-17

Last Posted Date: 2025-03-25

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 372

Registration Number: NCT06505590

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy

Recruiting

Conditions: Any Cancer

Interventions: Other: Supportive Care Pathway

First Posted Date: 2024-06-27

Last Posted Date: 2024-07-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 210

Registration Number: NCT06479057

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Phase 1

Recruiting

Conditions: Oligometastatic Disease
Solid Tumor, Adult

Interventions: Drug: all-trans retinoic acid
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2024-06-03

Last Posted Date: 2024-07-12

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 58

Registration Number: NCT06439888

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
Centre Léon Bérard, Lyon, France

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma

Phase 3

Recruiting

Conditions: Adult With Intermediate Low or Mid Rectal Adenocarcinoma

Interventions: Radiation: contact X-ray brachytherapy (CXB)

First Posted Date: 2024-05-07

Last Posted Date: 2025-01-01

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 212

Registration Number: NCT06402864

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

CARE1 Pragmatic Clinical Trial

Phase 3

Recruiting

Conditions: Metastatic Kidney Cancer
Metastatic Kidney Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Pembrolizumab
Drug: Cabozantinib
Drug: Axitinib
Drug: Lenvatinib

First Posted Date: 2024-04-15

Last Posted Date: 2025-01-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1250

Registration Number: NCT06364631

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria
🇨🇿
Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU), Brno, Czechia
🇨🇿
Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK), Hradec Kralove, Czechia

and more 43 locations

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Phase 3

Recruiting

Conditions: Cancer
Colo-rectal Cancer
Soft Tissue Sarcoma
Lung Cancer
Pancreas Cancer

Interventions: Other: Blood sampling
Drug: Tislelizumab
Drug: Placebo

First Posted Date: 2024-03-27

Last Posted Date: 2025-05-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 717

Registration Number: NCT06332274

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
HER2 Low Breast Carcinoma
HER2-positive Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Patritumab deruxtecan
Drug: Olaparib

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 152

Registration Number: NCT06298084

Locations: 🇫🇷
Gustave Roussy Institut, Villejuif, France

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Phase 2

Not yet recruiting

Conditions: Cancer

Interventions: Drug: Pembrolizumab and Olaparib
Drug: Pembrolizumab
Drug: Pembrolizumab adjuvant

First Posted Date: 2023-11-03

Last Posted Date: 2024-04-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 36

Registration Number: NCT06116578

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer

Phase 1

Recruiting

Conditions: Head and Neck Carcinoma
Adult Disease

Interventions: Biological: HPVDC injection level dose 1
Biological: HPVDC injection level dose 2
Biological: placebo injection level dose 1
Biological: placebo injection level dose 2

First Posted Date: 2023-08-23

Last Posted Date: 2025-01-20

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 24

Registration Number: NCT06007092

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy